PAI-1(纤溶酶原激活剂抑制剂-1,也称为 SERPINE1)是丝氨酸蛋白酶抑制剂(SERPIN)家族的成员,是两种主要哺乳动物纤溶酶原激活剂(尿型 (uPA) 和组织型 (tPA))的主要抑制剂。作为纤溶酶原激活的主要负调节剂,PAI-1是调节血栓形成和纤维蛋白溶解之间生理平衡的重要因素。PAI-1 是一种不稳定的分子,以四种不同的形式存在:活性、潜伏、裂解和靶结合形式。
高PAI-1水平与许多心血管疾病有关。PAI-1还在细胞迁移、粘附、衰老、癌症侵袭和组织重塑中发挥重要作用。此外,PAI-1水平已被广泛证实是乳腺癌的生物预后因素和其他癌症预后不良的标志。PAI-1 也是与非酒精性脂肪肝相关的血浆生物标志物之一。这些关联使得 PAI-1 成为一个颇具吸引力的药物靶点。
PAI-1 (Plasminogen activator inhibitor-1, also known as SERPINE1) is a member of serine protease inhibitor (SERPIN) family that acts as the primary inhibitor of two main mammalian plasminogen activators, urinary-type (uPA) and tissue-type (tPA). As the main negative regulator of plasminogen activation, PAI-1 is an essential factor in regulation of the physiological balance between thrombosis and fibrinolysis. PAI-1 is a labile molecule that exists in four different forms: active, latent, cleaved and target bound form.
High PAI-1 levels are associated with many cardiovascular diseases. PAI-1 also plays important roles in cell migration, adhesion, senescence, cancer invasion and tissue remodeling. Moreover, the PAI-1 level was extensively validated as the biological prognostic factor in breast cancer and as a marker of a poor prognosis in other cancers. PAI-1 is also one of the plasma biomarkers associated with nonalcoholic fatty liver disease. These associations have made PAI-1 an attractive pharmaceutical target.
D-Val-Leu-Lys-AMC TFA 是一种选择性纤溶酶(plasmin)荧光肽底物,可用于定量测定纤溶酶的酶活性,其 Ex 为 360-380 nm,Em 为 440-460 nm。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号